Autologous dendritic cell transplantation as an adjuvant treatment in pleomorphic lung carcinoma

Authors

Francisco S. Chung, Lung Center of the Philippines
Nelia S. Tan-Liu, Lung Center of the Philippines
Guia Imelda Elena R. Ladrera, Lung Center of the Philippines
Ramoncito S. Habaluyas, Lung Center of the Philippines
Ernesto Dj Yuson, Lung Center of the Philippines
Joselito J. Danguilan, Lung Center of the Philippines
Samuel D. Bernal, Globetek Science Foundation
Juanito A. Rubio, Lung Center of the Philippines
Maria Teresa A. Barzaga, De La Salle Medical and Health Sciences Institute

Publication Date

1-1-2013

Document Type

Article

Publication Title

Acta Medica Philippina

Abstract

We embarked on autologous dendritic cells (DC) transplantation as an adjuvant therapy with chemotherapy in a pleomorphic lung carcinoma patient. DC were isolated from PBMC and primed with the autologous tumor lysate. No adverse event was noted in DC transplantation. DC administration also correlated with immunomodulation, as evidenced by an approximately 5-fold increase in serum interferon gamma after 2 months. The utility of autologous DC transplantation may offer a clinical benefit with virtually no adverse event.

First Page

72

Last Page

75

APA Citation

Chung, F., Tan-Liu, N., Ladrera, G., Habaluyas, R., Yuson, E., Danguilan, J., Bernal, S., Rubio, J., & Barzaga, M. (2013). Autologous dendritic cell transplantation as an adjuvant treatment in pleomorphic lung carcinoma. Acta Medica Philippina, 47(4), 72-75. DOI:10.47895/amp.v47i4.1273